Originally Published EMDM
November 2003
INDUSTRY NEWS
In Brief |
Parylene Coating Centre Opens in Dublin
Specialty Coating Systems (SCS; Dublin, Ireland) has announced the opening of its new parylene coating facility in Dublin. Serving the fast-growing medical device industry in Ireland, the plant will complement SCS Europe’s multipurpose coating facility in Woking, UK. “To service our customers in
the medical device industry, SCS maintains multiple cleanroom facilities, FDA device and drug master files, and USP Class VI certifications,” says director of worldwide operations Terry Bush.
For more information, contact SCS Europe, Unit 52, Airways Industrial Estate, Dublin 17, Ireland; phone: +353 842 1172; fax: +353 842 1361; e-mail:
scssales@cooksonelectronics.com; Internet:
www.scscookson.com/europe.
NAMSA Completes Toxicology Facilities
A provider of nonclinical evaluations of medical devices and related products has opened two new facilities.
NAMSA Biomatech (Chasse-sur-Rhone, France) has expanded its animal laboratory facility by more than 15,000 sq ft. It will be used for routine biocompatibility evaluations of new devices. The second laboratory is located in Northwood, OH, USA, and has been operational since July. “This additional space enables NAMSA to offer a greater range of testing,” says director of toxicology Joe Carraway. The new vivarium accommodates the latest advancements in animal testing. The facility includes a modern surgical suite and extensive histopathology capabilities.
For more information, contact Biomatech S.A., Zone Industrielle de l’Islon, 115 rue Pasteur, 38670 Chasse-sur-Rhone, France; phone: +33 478 079234; fax: +33 472 240812; e-mail:
info@biomatech.fr; Internet: www.biomatech.fr.
Machine Supplier Receives Environmental Certification
 |
A subcontractor and supplier of precision machine tools recently received ISO 14001 certification for its two divisions.
Kern Micro- und Feinwerktechnik GmbH & Co. KG (Murnau, Germany) manufactures precision parts on a contract basis and also microdrilling and micromilling equipment.
For more information, contact Kern Micro- und Feinwerktechnik GmbH & Co. KG, Ammergauerstr. 11, D-82418 Murnau, Germany; phone: +49 8841 613047; fax: +49 8841 613040; e-mail:
mtsales@kern-microtechnic.com; Internet:
www.kern-microtechnic.com.
Dissolvable Films Facility Comes Together
A new 15,000-sq-ft facility slated for dissolvable films manufacturing is scheduled to open in Spring 2004.
Adhesives Research Inc. (Limerick, Ireland), developer and producer of pressure-sensitive adhesive tapes and specialty coatings, is adding the stand-alone building adjacent to its CGMP production facility that opened in March 2003. When the new plant opens this spring, the company will have a total of 215,000 sq ft under one roof at its US headquarters. The new plant will be used to manufacture custom adhesive systems and dissolvable films for the delivery of active ingredients found in pharmaceutical, over-the-counter, and nutraceutical products.
At the groundbreaking ceremony in August, Adhesives Research president and CEO Kären Olson addressed the importance of exploring new drug-delivery options. “The demand for these products is being driven by a need for a new delivery form.” She added that the new facility will enable the company “to offer expanded technical and production capabilities to serve these new markets.”
For more information, contact Adhesives Research Inc., Raheen Industrial Estate,
P.O. Box 101, Limerick, Ireland; phone: +353 61 300300; fax: +353 61 300700; e-mail:
mrobertson@arglobal.com; Internet: www.adhesivesresearch.com.
Platform Flow Technology Gains New Funding Stream
Tayside Flow Technologies (TFT; Dundee, UK), a medical technology company focused on the development of cardiovascular devices, has completed its third round of funding. The £1.3 million will allow TFT to begin human clinical trials in early 2004 with its 8-mm vascular graft designed to reduce the risk of amputation. “There has been strong interest from the big medical device companies in our technology,” says CEO Antony Odell.
TFT has developed a platform technology based on a new understanding of blood flow dynamics, called Spiral Laminar Flow (SLF). SLF is the naturally occurring flow pattern in healthy arterial systems. The innovation is based on a modification of the physical properties of commercially available synthetic grafts and stents to reduce downstream turbulence and wall pressure.
TFT is seeking to conclude an agreement with one or more trade partners.
For more information, contact Tayside Flow Technologies, Unit I, Prospect Business Centre, Gemini Crescent, Dundee Technology Park, Dundee DD2 1TY, UK; phone: +44 1382 598532; fax: +44 1382 598528; Internet:
www.tayflow.com.
Copyright ©2003 European Medical Device Manufacturer
